logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Breast Cancer Earlyonset

    FiltersReset Filters
    7 results

    • kadcyla

      (ADO-TRASTUZUMAB EMTANSINE)
      Genentech, Inc.
      Usage: KADCYLA is indicated for treating HER2-positive metastatic breast cancer in patients who have previously received trastuzumab and a taxane, or for early breast cancer in those with residual disease after neoadjuvant therapy. Patient selection should use an FDA-approved companion diagnostic.

    • kisqali

      (ribociclib)
      Novartis Pharmaceuticals Corporation
      Usage: KISQALI is indicated for adjuvant treatment of adults with HR-positive, HER2-negative early breast cancer at high risk of recurrence, and for adults with advanced or metastatic HR-positive, HER2-negative breast cancer, in combination with aromatase inhibitors or fulvestrant.

    • letrozole

      (Letrozole)
      Chartwell RX, LLC
      Usage: Letrozole Tablets are indicated for the adjuvant and extended adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer, as well as for first and second-line treatment of locally advanced or metastatic breast cancer in postmenopausal women.

    • letrozole

      (Letrozole Tablets)
      Yiling Pharmaceutical, Inc.
      Usage: Letrozole is indicated for the adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women, as well as for extended adjuvant therapy following tamoxifen. It is also used as a first and second-line treatment for advanced, locally advanced, or metastatic breast cancer in postmenopausal women.

    • perjeta

      (Pertuzumab)
      Genentech, Inc.
      Usage: PERJETA is indicated for treating adults with HER2-positive metastatic breast cancer in combination with trastuzumab and docetaxel, as well as for neoadjuvant and adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence, in combination with trastuzumab and chemotherapy.

    • phesgo

      (pertuzumab, trastuzumab, and hyaluronidase-zzxf)
      Genentech, Inc.
      Usage: PHESGO is indicated for combination with chemotherapy in adults with HER2-positive early breast cancer for neoadjuvant and adjuvant treatment, and for those with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy. Patient selection is based on an FDA-approved diagnostic test.

    • verzenio

      (abemaciclib)
      Eli Lilly and Company
      Usage: VERZENIO (abemaciclib) is indicated for adults with HR-positive, HER2-negative breast cancer. It is used in combination with endocrine therapy for early breast cancer at high risk of recurrence and for advanced or metastatic cases, either with an aromatase inhibitor, fulvestrant, or as monotherapy after prior treatments.